- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | 4 Analysts Have This To Say About Century Therapeutics | 2 | Benzinga.com | ||
| Di | Century Therapeutics startet Zelltherapie-Studie für Autoimmunerkrankungen | 1 | Investing.com Deutsch | ||
| Di | Century Therapeutics launches cell therapy trial for autoimmune diseases | 1 | Investing.com | ||
| Di | Century Therapeutics, Inc.: Century Therapeutics Announces Investigator-Initiated Phase 1/2 Trial of its iPSC-derived iNK Cell Therapy CNTY-101 in B-cell Mediated Autoimmune Diseases Sponsored by Internationally Renowned ... | 83 | GlobeNewswire (Europe) | - Investigator-initiated trial (IIT) to be led by pioneers of cell therapy in B-cell mediated autoimmune disease, the Schett/Mackensen group at Friedrich-Alexander University Erlangen-Nürnberg - -... ► Artikel lesen | |
| 13.01. | Century Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 30.12.24 | Century Therapeutics (NASDAQ:IPSC) Given New $4.00 Price Target at Piper Sandler | 2 | MarketBeat | ||
| 13.12.24 | Century Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| CENTURY THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 28.11.24 | Century Therapeutics Stages Highest Single Day Move In 11 Months As Casdin Capital Bumps Its Stake To 5.4% | 2 | Benzinga.com | ||
| 06.11.24 | HC Wainwright Cuts Century Therapeutics (NASDAQ:IPSC) Price Target to $5.00 | 4 | MarketBeat | ||
| 05.11.24 | Century Therapeutics, Inc.: Century Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates | 132 | GlobeNewswire (Europe) | - Expansion of Phase 1 CALiPSO-1 trial of CNTY-101 in autoimmune disease to include diffuse cutaneous systemic sclerosis and idiopathic inflammatory myopathy -- Overall response rate (ORR) of 83%... ► Artikel lesen | |
| 05.11.24 | Century Therapeutics, Inc.: Century Therapeutics Announces Upcoming Poster Presentations at the 2024 American Society of Hematology (ASH) Annual Meeting | 3 | GlobeNewswire (USA) | ||
| 05.11.24 | Century Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 05.11.24 | Century Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 26.09.24 | Century Therapeutics Appoints Morgan Conn As CFO | - | RTTNews | ||
| 26.09.24 | Century Therapeutics taps Morgan Conn as CFO | 1 | Seeking Alpha | ||
| 26.09.24 | Century Therapeutics, Inc.: Century Therapeutics Strengthens Leadership Team with Appointments of Chief Financial Officer and Chief Scientific Officer | 163 | GlobeNewswire (Europe) | - Morgan Conn, Ph.D., seasoned biotech executive with expertise in financing, business development, and corporate strategy, appointed as Chief Financial Officer - - Chad Cowan, Ph.D., cell therapy... ► Artikel lesen | |
| 26.09.24 | Century Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 15.08.24 | H.C. Wainwright tracks Century Therapeutics' trial progress, lowers stock PT | 7 | Investing.com | ||
| 08.08.24 | Century Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.08.24 | Century Therapeutics, Inc.: Century Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates | 123 | GlobeNewswire (Europe) | - Initiation of Phase 1 CALiPSO-1 Trial of CNTY-101 in Systemic Lupus Erythematosus, marking strategic expansion into autoimmune disease; protocol amended to include additional cohort of Lupus Nephritis... ► Artikel lesen |
Seite:
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 8,165 | +3,22 % | Evotec Aktie: Ein Abstieg ist zu befürchten | Die Evotec SE verzeichnet eine bedeutende Veränderung in ihrer Aktionärsstruktur. Der amerikanische Investmentkonzern T. Rowe Price Group hat seine Position am Hamburger Biotech-Unternehmen ausgebaut... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 0,932 | +2,98 % | Palatin Technologies, Inc.: Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy | Open label study designed to evaluate the safety, tolerability, and efficacy of bremelanotide in patients with Type 2 diabetic nephropathy
Demonstrated efficacy... ► Artikel lesen | |
| VIKING THERAPEUTICS | 33,130 | +0,73 % | Why Viking Therapeutics, Inc. (VKTX) Crashed Last Week | ||
| GALAPAGOS NV | 22,660 | +0,27 % | Galapagos inks agreement with Catalent for experimental CAR-T therapy | ||
| AFFIMED | 1,060 | +1,92 % | Affimed N.V.: Affimed Reports Promising Phase 1 Efficacy and Safety Data for AFM28 in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) | AFM28, a bispecific, tetravalent innate cell engager (ICE®) targeting CD123 and CD16A, achieved a 40% composite complete remission rate (CRcR) at the highest dose level (300 mg) in heavily pretreated... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 0,230 | -6,50 % | Cellectar Biosciences, Inc.: Cellectar Biosciences Provides Strategic Update on Clinical Development, Pipeline Programs and Corporate Restructuring | Evaluating strategic options for iopofosine I 131 a late-stage clinical program with compelling Phase 2 data and a substantial market opportunity Focusing on advancing radiotherapeutic assets including... ► Artikel lesen | |
| CYTOMX THERAPEUTICS | 0,880 | +2,92 % | CytomX Therapeutics Inc.: CytomX Therapeutics Announces 2025 Strategic Pipeline Priorities and Provides Corporate Update | - Encouraging progress supports near-term focus on lead wholly-owned program, CX-2051 (EpCAM PROBODY® ADC). Initial Phase 1a clinical data in advanced metastatic colorectal cancer (CRC) are anticipated... ► Artikel lesen | |
| CYTOKINETICS | 48,000 | -0,83 % | Cytokinetics, Incorporated: Cytokinetics Announces Start of AMBER-HFpEF, a Phase 2 Clinical Trial of CK-586 in Patients With Symptomatic Heart Failure With Preserved Ejection Fraction | SOUTH SAN FRANCISCO, Calif., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that AMBER-HFpEF (Assessment of CK-586 in a Multi-Center, Blinded Evaluation... ► Artikel lesen | |
| SPERO THERAPEUTICS | 0,830 | +0,12 % | Spero Therapeutics, Inc.: Spero Therapeutics Provides Business Update and Announces Interim Leadership Changes | Esther Rajavelu Appointed Interim President and Chief Executive Officer, Frank Thomas Appointed Chairman of the Board Interim Changes to Leadership Follow the Company's Response to a Wells Notice... ► Artikel lesen | |
| PERSONALIS | 6,050 | +3,86 % | Personalis Reports Preliminary Fourth Quarter and Full Year 2024 Revenue | FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported unaudited preliminary revenue for the fourth quarter and... ► Artikel lesen | |
| ATARA BIOTHERAPEUTICS | 6,500 | -3,70 % | Atara's T cell programmes hit with clinical hold after third-party site woes | ||
| PULMATRIX | 6,450 | +12,17 % | Pulmatrix: Über +100% Rendite für Anlegerclub NBC | Der No Brainer Club (NBC) hat erneut einen Volltreffer gelandet. Die Pulmatrix-Aktie, die Abonnenten des exklusiven Anlegerclubs im Frühsommer vorgestellt wurde, ist am Mittwoch zeitweise um über +100%... ► Artikel lesen | |
| AADI BIOSCIENCE | 2,760 | -7,38 % | Aadi Bioscience +72%: NBC-Kursrakete startet über Nacht | Riesengeschenk kurz vor Weihnachten: Mitglieder des exklusiven Anlegerclubs No Brainer Club (NBC) und Teilnehmer eines Webinars feiern am Freitag eine sensationelle Kursrakete. Die Aktie von Aadi Bioscience... ► Artikel lesen | |
| TELO GENOMICS | 0,102 | -0,97 % | Telo Genomics Corp.: Telo Genomics Closes Oversubscribed $2.5 Million Private Placement | Toronto, Ontario--(Newsfile Corp. - December 23, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (FSE: 3DOA) (the "Company" or "Telo") is pleased to announce that, further to its news release... ► Artikel lesen | |
| MINERVA NEUROSCIENCES | 2,040 | -2,86 % | Minerva Neurosciences Stock Hits 52-Week Low at $2.03 |
Das Unternehmen CENTURY THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,020 (-2,19 %) liegt der Kurs bei 0,890 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CENTURY THERAPEUTICS INC finden Sie auf Wallstreet Online.
